Literature DB >> 18178791

Stroke in chronic kidney disease: prevention and management.

Raymond R Townsend1.   

Abstract

The incidence of stroke is elevated among individuals with kidney disease. Traditional risk factors seem to account for much but not all of this excess risk. Blood pressure control is the most important aspect of stroke prevention. Multiple classes of antihypertensive agents, including diuretics, calcium channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers, have reduced stroke risk. Some physiologic and clinical evidence suggests that angiotensin II receptor blockers may offer superior benefit to that of angiotensin-converting enzyme inhibitors for the same level of blood pressure control; however, few head-to-head trials have compared these two agent classes directly using stroke as an outcome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18178791      PMCID: PMC3152267          DOI: 10.2215/CJN.03260807

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  30 in total

1.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.

Authors:  L Hansson; L H Lindholm; L Niskanen; J Lanke; T Hedner; A Niklason; K Luomanmäki; B Dahlöf; U de Faire; C Mörlin; B E Karlberg; P O Wester; J E Björck
Journal:  Lancet       Date:  1999-02-20       Impact factor: 79.321

2.  KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2006-05       Impact factor: 8.860

Review 3.  Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence.

Authors:  S G Chrysant
Journal:  J Hum Hypertens       Date:  2005-12       Impact factor: 3.012

4.  Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study.

Authors:  Toshiharu Ninomiya; Yutaka Kiyohara; Michiaki Kubo; Yumihiro Tanizaki; Yasufumi Doi; Ken Okubo; Yoshiyuki Wakugawa; Jun Hata; Yoshinori Oishi; Kentaro Shikata; Koji Yonemoto; Hideki Hirakata; Mitsuo Iida
Journal:  Kidney Int       Date:  2005-07       Impact factor: 10.612

5.  Intracranial aneurysm screening: indications and advice for practice.

Authors:  Gabriel J E Rinkel
Journal:  Lancet Neurol       Date:  2005-02       Impact factor: 44.182

6.  Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline.

Authors:  Larry B Goldstein; Robert Adams; Mark J Alberts; Lawrence J Appel; Lawrence M Brass; Cheryl D Bushnell; Antonio Culebras; Thomas J Degraba; Philip B Gorelick; John R Guyton; Robert G Hart; George Howard; Margaret Kelly-Hayes; J V Ian Nixon; Ralph L Sacco
Journal:  Stroke       Date:  2006-05-04       Impact factor: 7.914

7.  Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

Authors:  Joachim Schrader; Stephan Lüders; Anke Kulschewski; Frank Hammersen; Kerstin Plate; Jürgen Berger; Walter Zidek; Peter Dominiak; Hans Christoph Diener
Journal:  Stroke       Date:  2005-05-05       Impact factor: 7.914

8.  Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial.

Authors:  Michael A Weber; Stevo Julius; Sverre E Kjeldsen; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John H Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; M Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

9.  Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.

Authors:  Mahboob Rahman; Sara Pressel; Barry R Davis; Chuke Nwachuku; Jackson T Wright; Paul K Whelton; Joshua Barzilay; Vecihi Batuman; John H Eckfeldt; Michael A Farber; Stanley Franklin; Mario Henriquez; Nelson Kopyt; Gail T Louis; Mohammad Saklayen; Carole Stanford; Candace Walworth; Harry Ward; Thomas Wiegmann
Journal:  Ann Intern Med       Date:  2006-02-07       Impact factor: 25.391

10.  Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.

Authors:  Koon Teo; Salim Yusuf; Peter Sleight; Craig Anderson; Farouk Mookadam; Barbara Ramos; Lutz Hilbrich; Janice Pogue; Helmut Schumacher
Journal:  Am Heart J       Date:  2004-07       Impact factor: 4.749

View more
  2 in total

1.  Ischemic stroke among the patients with end-stage renal disease who were undergoing maintenance dialysis.

Authors:  San Jung; Seok-Beom Kwon; Sung-Hee Hwang; Jung Woo Noh; Young-Ki Lee
Journal:  Yonsei Med J       Date:  2012-09       Impact factor: 2.759

2.  Absolute risk and risk factors for stroke mortality in patients with end-stage kidney disease (ESKD): population-based cohort study using data linkage.

Authors:  Nicole Louise De La Mata; Maria Alfaro-Ramirez; Patrick J Kelly; Philip Masson; Rustam Al-Shahi Salman; Angela C Webster
Journal:  BMJ Open       Date:  2019-02-22       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.